Investors are increasingly interested in companies like Galmed Pharmaceuticals, Protagenic Therapeutics, and Hepion Pharmaceuticals for their innovative approaches in biotech. Galmed Pharmaceuticals is developing Aramchol for liver and fibro-inflammatory diseases,…
Insitro is downsizing its workforce by 22%, reflecting broader industry challenges in biotech fundraising. Led by Daphne Koller, Insitro combines machine learning with drug discovery, serving as an innovation leader.…
Swiss biotech sector shows resilience and innovation amidst a challenging global economy, with a significant rise in R&D investment in 2024. In 2025, the Swiss Biotech Report reveals SFr2.6 billion…
Otello Stampacchia, founder of Omega Funds, is noted for his candid critiques in the biotech investment world. Omega Funds, established in 2003, has invested in over 150 companies, contributing to…
Biopharmaceuticals are transforming healthcare by enabling personalized medicine, with treatments tailored to individual genetic codes. Biopharma combines biology and pharmaceuticals, using biotechnology to develop therapies that target diseases at the…
Edesa Biotech announces CFO Stephen Lemieux's departure, retaining him as a senior financial advisor. Peter J. Weiler is appointed as the new CFO, bringing extensive experience in biotechnology and pharmaceuticals.…
Peter J. Weiler joins Edesa Biotech as Chief Financial Officer in May, marking a pivotal transition for the company and the broader biotech industry. Weiler brings extensive experience from Exzell…
Edesa Biotech appoints Peter J. Weiler as the new CFO, effective May 1, 2025, signaling a strategic shift. Weiler brings a robust track record in biotech and pharma, previously leading…
Edesa Biotech appoints Peter J. Weiler as the new Chief Financial Officer, effective May 1, 2025, to lead financial strategy in developing therapies for immuno-inflammatory diseases. Stephen Lemieux transitions to…
Relay Therapeutics is undergoing significant restructuring, including three layoff rounds within a year, to tackle economic challenges and refocus on key clinical goals. The company has slashed its research budget…